<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02005653</url>
  </required_header>
  <id_info>
    <org_study_id>IM0603-CEC-VCRC</org_study_id>
    <nct_id>NCT02005653</nct_id>
  </id_info>
  <brief_title>Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection</brief_title>
  <official_title>Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection: Double Blind Randomised Clinical Trial (RCT) to Study the Efficacy of Different Co-administration and Sequential Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indian Council of Medical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indian Council of Medical Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diethylcarbamazine (DEC) essentially a micro-filaricidal drug is given for 12 days as
      standard treatment for the clearance of W. bancrofti infection. It takes about one year for
      the individuals to completely clear the microfilaria from the blood. It takes another two to
      four years to clear the antigen. The aim of the present study is to shorten the time taken
      for clearing the Mf and antigen from the blood either by co-administration or sequential
      administration of a macrofilaricidal drug, Albendazole or doxycycline. This study is a
      randomized, double blind, controlled clinical trial to study the efficacy of these drug
      combinations in complete clearance the Mf and antigen from the blood in shorter span of 180
      days and 365 days respectively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

      Lymphatic dwelling parasite W. bancrofti is the most common cause of secondary lymphoedema.
      Till today, there is no effective treatment protocol for the complete clearance of W.
      bancrofti infection, in a short duration of time.

      Methods:

      The investigators conducted a double blind RCT under field conditions recruiting 146
      asymptomatic W. bancrofti infected individuals. Participants were randomly assigned one of
      the four regimens for 12 days, DEC 300 mg + Doxycycline 100 mg co-administration or DEC 300
      mg + Albendazole 400 mg co-administration or DEC 300 mg + Albendazole 400 mg sequential
      administration or control regimen DEC 300 mg. Participants were followed up at 13, 26 and 52
      weeks post-treatment for the clearance of infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete clearance of mf in 80% of the infected</measure>
    <time_frame>At 13th week (91 days) post therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete clearance Mf and complete clearance of antigen from the infected</measure>
    <time_frame>26 and 52 weeks post therapy</time_frame>
    <description>a)Complete clearance of Mf by 26 weeks (180 days) post therapy. b) Complete clearance of antigen by 52 weeks (365days) post therapy</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Filarial; Infestation</condition>
  <arm_group>
    <arm_group_label>DEC + ALB sequential</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet at 30 days post treatment sequentially</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEC + ALB co-admin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet per day given orally as single dose for 12 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEC + DOXY co-admin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diethylcarbamazine 300 mg tablet and Doxycycline 100 mg per day given orally as single dose for 12 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diethylcarbamazine (DEC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diethylcarbamazine 300 mg tablet as single dose orally per day for 12 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diethylcarbamazine</intervention_name>
    <description>Diethylcarbamazine 300 mg tablet as single dose per day for 12 days</description>
    <arm_group_label>DEC + ALB sequential</arm_group_label>
    <arm_group_label>DEC + ALB co-admin</arm_group_label>
    <arm_group_label>DEC + DOXY co-admin</arm_group_label>
    <arm_group_label>Diethylcarbamazine (DEC)</arm_group_label>
    <other_name>DEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>Experimental</description>
    <arm_group_label>DEC + ALB sequential</arm_group_label>
    <arm_group_label>DEC + ALB co-admin</arm_group_label>
    <other_name>Alb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Experimental</description>
    <arm_group_label>DEC + DOXY co-admin</arm_group_label>
    <other_name>Doxy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Residing in or around Pondicherry and adjoining Tamilnadu areas

          -  Night blood microfilaria counts &gt; 10 mf/ml by membrane filtration

          -  No history of treatment for filarial infection for the last two years at least

          -  Willing for home visits by the staff of the center

          -  Willing to give written informed consent

        Exclusion Criteria:

          -  Body weight less than 30 kg

          -  Hepatic or renal disease as evidenced by clinical or biochemical abnormalities. -
             concurrent illness like hypertension, diabetes mellitus, cardiac conditions and
             epilepsy requiring chronic medication

          -  Psychiatric illness

          -  Patients under tetracycline or doxycycline therapy

          -  History of de-worming by albendazole or other anti-helminthic during last one year

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lourduraj J De Britto, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vector Control Research Centre, Indian Council of Medical Research, Pondicherry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vector Control Research Centre</name>
      <address>
        <city>Pondicherry</city>
        <zip>605006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>December 6, 2013</last_update_submitted>
  <last_update_submitted_qc>December 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indian Council of Medical Research</investigator_affiliation>
    <investigator_full_name>Lourduraj John De Britto</investigator_full_name>
    <investigator_title>Scientist-E (Medical)</investigator_title>
  </responsible_party>
  <keyword>Lymphatic filariasis</keyword>
  <keyword>W. bancrofti</keyword>
  <keyword>DEC</keyword>
  <keyword>Albendazole</keyword>
  <keyword>Doxycycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parasitic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Albendazole</mesh_term>
    <mesh_term>Diethylcarbamazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

